Daily Life
7 pages in this section, most recently updated September 4, 2026.
- 01
Alcohol on a GLP-1: what the labels say (almost nothing), what the trials found, and how to drink if you do
The Zepbound, Mounjaro, Wegovy and Ozempic labels carry no alcohol interaction. That is not the same as no issue. Hypoglycaemia with other diabetes drugs, pancreatitis, slower gastric emptying, calories and the 2025 semaglutide alcohol-use-disorder trial, sourced.
Updated September 4, 2026
- 02
Surgery, sedation and endoscopy on a GLP-1: the label aspiration warning and what the anaesthesia societies say to do
Every GLP-1 label now carries a warning about pulmonary aspiration under general anaesthesia or deep sedation. It tells you to inform your clinicians and stops there. This guide sets out the label text, the ASA 2023 statement, the 2024 multi-society guidance, and what to do the week before a procedure.
Updated September 4, 2026
- 03
Nausea on a GLP-1: the label rates, when it peaks, and a management routine that clinicians actually recommend
Nausea is the most common adverse reaction on every GLP-1 label. This guide gives the trial rates for Wegovy and Zepbound, explains why escalation weeks are worst, and sets out the eating, timing and escalation strategies published in clinical guidance, with the warning signs that mean it is not ordinary nausea.
Updated September 4, 2026
- 04
Hydration and constipation on a GLP-1: the kidney warning behind the water advice, and a constipation plan with sources
Every GLP-1 label warns of acute kidney injury from volume depletion, and constipation affects up to a quarter of people on semaglutide. What the labels say, what the AGA constipation guideline recommends, and a practical routine for fluids, fibre and when to escalate.
Updated September 4, 2026
- 05
Hair shedding on a GLP-1: the label rates, why it is tied to weight loss, and what usually happens next
Hair loss appears in the Wegovy and Zepbound adverse-reaction tables at 3 to 6 percent. The Zepbound label says it was associated with weight reduction and far more common in women. What the labels report, what telogen effluvium is, and the questions worth asking before assuming the drug is the cause.
Updated September 4, 2026
- 06
Keeping muscle on a GLP-1: what the body-composition substudies found and the protein and training evidence that answers them
Roughly a quarter to two-fifths of weight lost on semaglutide or tirzepatide in the trial substudies was lean mass. That is normal for weight loss, and it is also modifiable. The DXA data from STEP 1 and SURMOUNT-1, the resistance-training and protein trials, and a practical weekly plan.
Updated September 4, 2026
- 07
When a dose step is not going well: what the labels say about slowing down, staying put and stepping back
The escalation schedules for Wegovy and Zepbound are on the label, and so are the options when a step is not tolerated: delay 4 weeks, hold at a lower maintenance dose, step down from 2.4 to 1.7 mg. What the labels actually permit, what they do not, and how to have the conversation with your prescriber.
Updated September 4, 2026